Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chronic schizophrenia: Do BMI and orexin-A levels play a role?

Key clinical point: Elevated orexin-A levels positively correlate with higher body mass index (BMI) which seems to be correlated with fewer negative symptoms among inpatients with chronic schizophrenia (CS); however, there is no direct correlation between orexin-A levels and clinical symptoms.

Major finding: Plasma orexin-A levels were higher in the obesity group (1.24±1.45 ng/mL) than the nonoverweight (0.85±1.18 ng/mL) and overweight (0.97±1.15 ng/mL) groups. Higher BMIs were associated with higher orexin-A levels (P less than .001) and fewer negative symptoms (P = .003). No direct correlation was observed between plasma orexin-A levels and clinical symptoms.

Study details: This study assessed orexin-A levels and clinical symptoms in nonoverweight (n = 176), overweight (n = 96), and obese (n = 52) Chinese inpatients with CS.

Disclosures: This study was supported by the National Natural Science Foundation of China, the Anhui Key Research and Development Program, and the Scientific Research Foundation of the Institute for Translational Medicine. The authors declared no conflicts of interest.

Citation:

Liu Z et al. Nord J Psychiatry. 2020 May 04. doi: 10.1080/08039488.2020.1755995.